We hypothesized that early nongenetic adaptation mechanisms to BCR inhibitors might exist, allowing CLL cells to survive the lack of recirculation to immune niches and microenvironmental interactions that provide them with antiapoptotic signals. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.